Oyetunji Aderonke, Huelga Christian, Bunte Kailee, Tao Rachel, Bellman Val
University of Missouri Kansas City, Psychiatry Residency Training Program, Kansas City, MO.
Kansas City University, College of Osteopathic Medicine, Kansas City, MO.
AIMS Public Health. 2023 Jul 21;10(3):610-626. doi: 10.3934/publichealth.2023043. eCollection 2023.
Depression and suicidality are significant challenges faced by cancer patients, particularly those in advanced stages of the disease or nearing the end of life. Conventional antidepressant therapies often have limited effectiveness or delayed onset of action, making the exploration of alternative treatments crucial. The use of ketamine as a potential treatment for depression and suicidality in cancer and terminal patients has gained considerable attention in recent years. This review article aims to provide a comprehensive analysis of the current data regarding the efficacy and safety of ketamine in this specific population. This review presents an overview of clinical trials and case studies investigating the use of ketamine in this population. It explores the effectiveness of ketamine as a standalone treatment or in combination with other interventions. Furthermore, the article addresses the limitations and future directions of research in this field. It highlights the need for larger, well-controlled studies with long-term follow-up to establish the efficacy, safety and optimal treatment parameters of ketamine for depression and suicidality in palliative care.
抑郁症和自杀倾向是癌症患者面临的重大挑战，尤其是那些处于疾病晚期或接近生命终点的患者。传统的抗抑郁疗法往往效果有限或起效延迟，因此探索替代治疗方法至关重要。近年来，氯胺酮作为癌症和晚期患者抑郁症和自杀倾向的潜在治疗方法受到了广泛关注。这篇综述文章旨在对氯胺酮在这一特定人群中的疗效和安全性的现有数据进行全面分析。这篇综述概述了调查氯胺酮在这一人群中使用情况的临床试验和案例研究。它探讨了氯胺酮作为单一治疗方法或与其他干预措施联合使用的有效性。此外，文章还讨论了该领域研究的局限性和未来方向。它强调需要进行更大规模、严格控制且长期随访的研究，以确定氯胺酮在姑息治疗中治疗抑郁症和自杀倾向的疗效、安全性和最佳治疗参数。
